Nilotinib

Recent Results in Cancer Research

Volumn 201, Issue , 2014, Pages 67-80

  Ostendorf, Benjamin N ^a   le Coutre, Philipp ^a   Kim, Theo D ^a   Quintás Cardama, Alfonso ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BIOLOGICAL MARKER; DASATINIB; IMATINIB; NILOTINIB; RIFAMPICIN; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANEMIA; ARTICLE; BRAIN HEMORRHAGE; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; EFFUSION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; GRAPEFRUIT JUICE; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; IC50; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY (TOPIC); MYELOID LEUKEMIA; NEUTROPENIA; NONHUMAN; PANCREATITIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; STRUCTURE ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84906932448     PISSN: 00800015     EISSN: 21976767     Source Type: Book Series    
DOI: 10.1007/978-3-642-54490-3_3     Document Type: Article

References (50)

1. Aichberger KJ, Herndlhofer S, Schernthaner G-H et al (2011) Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 86: 533-539.
2. Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8: 1018-1029.
3. Baccarani M, Cortes J, Pane F (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27: 6041-6051.
4. Bradeen HA, Eide CA, O'Hare T et al (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108: 2332-2338.
5. Cortes J, O'Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104: 2204-2205.
6. Deininger MWN, O'Brien SG, Ford JM et al (2003) Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21: 1637-1647.
7. Druker BJ, Guilhot F, O'Brien S et al (2006) Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. J Clin Oncol 24: 338S-338S.
8. Druker BJ, Tamura S, Buchdunger E, Ohno S (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566.
9. Ernst T, La Rosee P, Mueller MC, Hochhaus A (2011) Bcr-Abl mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am 25: 997-1008.
10. Giles FJ, Abruzzese E, Rosti G et al (2010) Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 24: 1299-1301.
11. Giles FJ, Kantarjian HM, le Coutre PD et al (2012) Nilotinib is effective in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26: 959-962.
12. Giles FJ, Larson RA, Kantarjian HM (2008) Nilotinib in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib-Giles et al. 26 (15 Supplement): 7017-ASCO Meeting Abstracts. J Clin Oncol 26: 7017.
13. Giles FJ, le Coutre PD, Pinilla-Ibarz J et al (2013) Nilotinib in imatinib-resistant or imatinibintolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27: 107-112.
14. Golemovic M, Verstovsek S, Giles F et al (2005) AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11: 4941-4947.
15. Gorre ME, Mohammed M, Ellwood K et al (2001) Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification. Science 293: 876-880.
16. Haouala A, Widmer N, Duchosal MA et al (2011) Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117: E75-E87.
17. Hochhaus A, Saglio G, Larson RA et al (2013) Nilotinib is associated with a reduced incidence of Bcr-Abl mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 121: 3703-3708.
18. Jain P, Kantarjian H, Nazha A et al (2013) Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities. Blood 121: 4867-4874.
19. Kagan M, Tran P, Fischer V et al (2005) Safety, pharmacokinetics (PK), metabolism, and mass balance of [C-14]-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects. Blood 106: 302B-302B.
20. Kantarjian H, Giles F, Wunderle L et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551.
21. Kantarjian HM, Giles F, Gattermann N et al (2007) Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110: 3540-3546.
22. Kantarjian HM, Giles FJ, Bhalla KN et al (2011a) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month followup results. Blood 117: 1141-1145.
23. Kantarjian HM, Hochhaus A, Saglio G et al (2011b) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12: 841-851.
24. Kim TD, Rea D, Schwarz M et al (2013) Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 27: 1316-1321.
25. Larson RA, Hochhaus A, Hughes TP et al (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26: 2197-2203.
26. Larson RA, Hochhaus A, Saglio G et al. (2013) Nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year update. J Clin Oncol (suppl) 31: abstr. 7052.
27. le Coutre P, Ottmann OG, Giles F et al (2008) Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood 111: 1834-1839.
28. le Coutre P, Rea D, Abruzzese E et al (2011) Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 103: 1347-1348.
29. le Coutre PD, Giles FJ, Hochhaus A et al (2012) Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month followup results. Leukemia 26: 1189-1194.
30. Mahon F-X (2012) Is going for cure in chronic myeloid leukemia possible and justifiable? Hematology Am Soc Hematol Educ Program 2012: 122-128.
31. Mahon F-X, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 11: 1029-1035.
32. Manley PW, Breitenstein W, Brüggen J et al (2004) Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDCFR kinases. Bioorg Med Chem Lett 14: 5793-5797.
33. O'Hare T, Eide CA, Deininger MWN (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242-2249.
34. O'Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65: 4500-4505.
35. Quintás-Cardama A, Kantarjian H, Cortes J (2012) Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 12: 337-340.
36. Ray A, Cowan-Jacob SW, Manley PW et al (2007) Identification of Bcr-Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109: 5011-5015.
37. Rea D, Rousselot P, Nicolini FE et al (2011) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia (CML) patients (pts) with stable undetectable Bcr-Abl transcripts: results from the French CML group (FILMC). ASH Annual Meeting Abstracts 118: 604.
38. Redaelli S, Mologni L, Rostagno R et al (2012) Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 87: E125-E128.
39. Rix U, Hantschel O, Duernberger G et al (2007) Chemical proteomic profiles of the Bcr-Abl inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets. Blood 110: 4055-4063.
40. Ross DM, Branford S, Seymour JF et al (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122: 515-522.
41. Saglio G, Kim D-W, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: 2251-2259.
42. Sawyers CL, Hochhaus A, Feldman E et al (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530-3539.
43. Shah NP, Nicoll JM, Nagar B et al (2002) Multiple Bcr-Abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
44. Talpaz M, Silver RT, Druker BJ (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99: 1928-1937.
45. Tanaka C, Yin OQP, Sethuraman V et al (2009) Clinical pharmacokinetics of the Bcr-Abl tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87: 197-203.
46. Tanaka C, Yin OQP, Smith T et al (2011) Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 51: 75-83.
47. von Bubnoff N, Manley PW, Mestan J et al (2006) Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108: 1328-1333.
48. Weisberg E, Manley P, Mestan J et al (2006) AMN107 (nilotinib): a novel and selective inhibitor of Bcr-Abl. Br J Cancer 94: 1765-1769.
49. Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129-141.
50. Yin OQP, Gallagher N, Li A et al (2010) Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 50: 188-194.